Strategic Incorporation of Polarity in Heme-Displacing Inhibitors of Indoleamine-2,3-dioxygenase-1 (IDO1)
- 10 March 2020
- journal article
- letter
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 11 (4) , 550-557
Abstract
Indoleamine-2,3-dioxygenase-1 (IDO1) has emerged as a target of significant interest to the field of cancer immunotherapy, as the upregulation of IDO1 in certain cancers has been linked to host immune evasion and poor prognosis for patients. In particular, IDO1 inhibition is of interest as a combination therapy with immune checkpoint inhibition. Through an Automated Ligand Identification System (ALIS) screen, a diamide class of compounds was identified as a promising lead for the inhibition of IDO1. While hit 1 possessed attractive cell-based potency, it suffered from a significant right-shift in a whole blood assay, poor solubility, and poor pharmacokinetic properties. Through a physicochemical property-based approach, including a focus on lowering AlogP98 via the strategic introduction of polar substitution, compound 13 was identified bearing a pyridyl oxetane core. Compound 13 demonstrated improved whole blood potency and solubility, and an improved pharmacokinetic profile resulting in a low predicted human dose.Keywords
This publication has 36 references indexed in Scilit:
- The Clinicopathological and Prognostic Significance of IDO1 Expression in Human Solid Tumors: Evidence from a Systematic Review and Meta-AnalysisCellular Physiology and Biochemistry, 2018
- Discovery of IDO1 Inhibitors: From Bench to BedsideCancer Research, 2017
- Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) InhibitorsJournal of Medicinal Chemistry, 2015
- Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHROncotarget, 2014
- Indoleamine 2,3 dioxygenase and metabolic control of immune responsesTrends in Immunology, 2013
- An expanding range of targets for kynurenine metabolites of tryptophanTrends in Pharmacological Sciences, 2013
- Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan DepletionCancer Research, 2012
- Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic PerspectivesClinical Cancer Research, 2011
- Indoleamine 2,3-dioxygenase and tumor-induced toleranceJournal of Clinical Investigation, 2007
- The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor ζ-Chain and Induce a Regulatory Phenotype in Naive T CellsThe Journal of Immunology, 2006